Curocell Inc. (KOSDAQ:372320)

South Korea flag South Korea · Delayed Price · Currency is KRW
62,400
-1,500 (-2.35%)
At close: Apr 27, 2026
131.97%
Market Cap 938.44B
Revenue (ttm) n/a
Net Income (ttm) -46.31B
Shares Out 15.04M
EPS (ttm) -3,232.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 231,078
Average Volume 185,434
Open 62,500
Previous Close 63,900
Day's Range 60,100 - 63,100
52-Week Range 25,850 - 65,800
Beta 1.19
RSI 66.49
Earnings Date Mar 27, 2026

About Curocell

Curocell Inc., a cell gene therapy development company, engages in the development and manufacturing of pharmaceuticals. It provides research and development services; and OVercome Immune Suppression (OVIS), a proprietary platform technology designed to get away from exhaustion induced by immune checkpoint receptors. The company is also involved in the development of CD19 CAR-T treatment, blood cancer CAR-T, solid cancer CAR-T, and allogeneic CAR-T. Curocell Inc. was founded in 2016 and is headquartered in Daejeon, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 372320
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.